Recombinant EPH Receptor A3 anticorps

N° du produit ABIN7543439

Cet anticorps Lapin Monoclonal détecte spécifiquement EPH Receptor A3 dans WB, ELISA, FACS, IF, IP, in vivo et SPR. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant EPH Receptor A3 anticorps (ABIN7543439)

Antigène: EPH Receptor A3 (EPHA3)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp EPH Receptor A3 est non-conjugé

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunofluorescence (IF), Immunoprecipitation (IP), In vivo Studies (in vivo), Surface Plasmon Resonance (SPR)

Clone: IIIA4

Détail du produit anti-EPH Receptor A3 anticorps

Fonction: Anti-EpHA3 [IIIA4], Rabbit IgG, kappa

Specificité: The antibody binds to the native EphA3 globular ephrin-binding domain. The antibody targets a site closely adjacent to the heterotetramerization site on the N-terminal of EPHA3's extracellular domain adjacent to the ligand-binding site and has a high affinity for EPHA3.

Réactivité croisée: Souris

Attributs du produit:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogène: The original antibody was prepared by intraperitoneal immunization of a BALB/c mouse with LK63 cells.

Isotype: IgG kappa

Information d'application

Indications d'application: This antibody was used for detection of hek expressed on LK63 cells by flow cytometry. Hek antigen was immunoprecipitated using the antibody from 125I-labeled LK63 cell lysates (Boyd et al., 1992, PMID: 1737782). The specificity of the chimeric version of the antibody was confirmed by ELISA analysis (US8664365). In a LK63 xenograft model, administration of the antibody inhibited the tumor growth, decreasing the spreading from the bone marrow to the spleen and other organs and increases the latency of the disease. Similar effects were observed in LK63 EPHA3 knock down xenografts. Further, antibody treatment of a xenograft model using EPHA3-transfected Reh, showed reduction in the bone marrow engraftment and increases the latency of the disease (Charmsaz et al., 2016, PMID: 27922598). The antibody bound to the native EphA3 globular ephrin-binding domain with subnanomolar affinity (KD ~ 0.5 nM) (Smith et al., 2004, PMID: 14660665). The antibody specifically stained EphA3 in 95 % of human tumor tissues from a broad range of cancer types (Vail et al. 2014, PMID: 25125683). The humanized version of the antibody (KB004), was tested in a multi-center Phase 1/2 trial, in patients with EphA3-positive hematologic neoplasms, including Chronic Myelogenous Leukemia, Acute Myeloid Leukemia, Acute lymphoblastic leukemia, Myelodysplastic Syndrome.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur EPH Receptor A3

Antigène: EPH Receptor A3 (EPHA3)

Autre désignation: EpHA3

Sujet: Ephrin type-A receptor 3, EPH-like kinase 4, EK4, hEK4, HEK, Human embryo kinase, Tyrosine-protein kinase TYRO4, Tyrosine-protein kinase receptor ETK1, Eph-like tyrosine kinase 1, III.A4

UniProt: P29320

Pathways: Signalisation RTK, Regulation of Cell Size